Drug intelligence / Profile preview

ViscoGel

Development stage: Phase 2
Lead developer: Viscogel
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

ViscoGel is an investigational pharmaceutical developed by Viscogel AB. It is being evaluated for its safety when administered alone and for its safety and efficacy as an adjuvant in the Act-HIB® vaccine. The primary goal of its use as an adjuvant is to enhance the quantitative and qualitative immune response to the vaccine.

Brand names: ViscoGel

Beyond the preview

Go deeper on ViscoGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViscoGel.

Explore the full profile